Telix Pharmaceuticals

Telix Pharmaceuticals Overview

  • Founded
  • 2015
Founded
  • Status
  • Public
  • Stock Symbol
  • TLX
Stock Symbol
  • Investments
  • 4
  • Share Price
  • $1.08
  • (As of Wednesday Closing)

Telix Pharmaceuticals General Information

Description

Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing molecularly-targeted radiation therapy to address the unmet needs in the management of prostate, renal (kidney) and glioblastoma (brain) cancer. Geographically, it operates in Australia, the United States, Belgium, and Japan.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Diagnostic Equipment
Other Industries
Other Devices and Supplies
Therapeutic Devices
Stock Exchange
ASX
Primary Office
  • 55 Flemington Road
  • Suite 401
  • North Melbourne, Victoria 3051
  • Australia
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Telix Pharmaceuticals Stock Performance

(As of Tuesday closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.08 $1.07 $0.43 - $1.33 $275M 254M 908K

Telix Pharmaceuticals Financials Summary

In Thousands,
USD
TTM 31-Mar-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 125,699 245,110 83,046 43,526
Revenue 2,422 146
EBITDA (17,082) (11,952) (4,905)
Net Income (19,370) (10,324) (4,886)
Total Assets 71,834 54,033 39,853
Total Debt 1,492 1,218 269
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Telix Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Telix Pharmaceuticals‘s full profile, request access.

Request a free trial

Telix Pharmaceuticals Executive Team (9)

Name Title Board Seat Contact Info
Douglas Cubbin Chief Financial Officer
Gabriel Liberatore Chief Operating Officer
Jyoti Arora Ph.D Director of Operations
Michael Wheatcroft Ph.D Director of Research and Development
David Cade Chief Business Officer and Head of Investor Relations

Telix Pharmaceuticals Board Members (5)

Name Representing Role Since
Andreas Kluge MD Telix Pharmaceuticals Co-Founder, Chief Medical Officer & Board Member 000 0000
Christian Behrenbruch Ph.D Self Co-Founder, Chief Executive Officer & Board Member 000 0000
Kevin McCann Telix Pharmaceuticals Independent, Non-Executive Chairman 000 0000
Mark Nelson Ph.D Telix Pharmaceuticals Board Member 000 0000
Oliver Buck Telix Pharmaceuticals Non-Executive Director 000 0000

Telix Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Telix Pharmaceuticals‘s full profile, request access.

Request a free trial

Telix Pharmaceuticals Investments & Acquisitions (4)

To view Telix Pharmaceuticals‘s complete investment and acquisition history, request access »
Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000 24-Dec-2018 000000000000000000 00.000 Distributors (Healthcare) 000000000 00000000000 00.0
00000 000000 11-Sep-2018 000000000000000000 0000 Therapeutic Devices 000000000 00000000000 00.0
00000 0000000 24-Oct-2017 00000 0000000 Diagnostic Equipment
Therapeia 18-Jan-2017 Merger/Acquisition Drug Discovery 000000000 00000000000 00.0

Telix Pharmaceuticals Subsidiaries (2)

Company Name Industry Location Founded
ANMI Distributors (Healthcare) Liège, Belgium 2015
000000000 Drug Discovery Dresden, Germany 0000